Hanall Biopharma reported preliminary Q3 2026 results (consolidated): Revenue of KRW 39.9 billion (-2.2% year over year), operating profit of KRW 1.3 billion (+265.1% year over year), net profit of KRW 3.1 billion (+924.2% year over year).

Hanall Biopharma reported preliminary Q3 2026 results (consolidated): Revenue of KRW 39.9 billion (-2.2% year over year), operating profit of KRW 1.3 billion (+265.1% year over year), net profit of KRW 3.1 billion (+924.2% year over year).

Written in code from the structured data of the filing. Reference information, not investment advice.

Key figures

Period

Q3 2026

Basis

Consolidated

Revenue

KRW 39.9 billion (-2.2% year over year)

Operating profit

KRW 1.3 billion (+265.1% year over year)

Net profit

KRW 3.1 billion (+924.2% year over year)

Filing facts

Filing type

Preliminary Earnings

Report name

Preliminary Consolidated Operating Results (Fair Disclosure)

Filed

Oct 28, 2026

Receipt number

20261028800653